参考文献/References:
[1] Reddy VY, Mobius-Winkler S, Miller MA, et al. Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology)[J]. J Am CollCardiol, 2013, 61:2551-2556.
[2] Reddy VY, Doshi SK, Kar S, et al. PREVAIL and PROTECT AF Investigators. 5-Year Outcomes After Left Atrial Appendage Closure: From the PREVAIL and PROTECT AF Trials[J]. J Am CollCardiol, 2017, 70:2964-2975.
[3] Boersma LV, Ince H, Kische S, et al. Evaluating Real-World Clinical Outcomes in Atrial Fibrillation Patients Receiving the WATCHMAN Left Atrial Appendage Closure Technology: Final 2-Year Outcome Data of the EWOLUTION Trial Focusing on History of Stroke and Hemorrhage[J]. CircArrhythmElectrophysiol, 2019, 12: e006841.
[4] Holmes DR Jr, Kar S, Price MJ, et al. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial[J]. J Am CollCardiol, 2014, 64:1-12.
[5] 汤学超,白 元,张志钢,等. 左心耳封堵器临床研究进展[J]. 介入放射学杂志,2017,26:281-284.